DVC1-0401 / I’rom Group - LARVOL DELTA

Long-Term Outcomes of Lentivirus-Based Neuroprotective Gene Therapy for Retinitis Pigmentosa: A Phase I/IIa Investigator-Initiated Clinical Trial of DVC1-0401 (ARVO 2026) - "These results suggest that neuroprotective gene therapy may delay vision loss in RP. If confirmed in larger trials, this strategy could offer a broadly applicable means of preserving sight across diverse RP genotypes."

Clinical • First-in-human • Gene therapy • P1/2 data • Cataract • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa